Method for predicting the response to an anti-her2 containing therapy and/or chemotherapy in patients with breast cancer

A method for predicting a response and/or survival after anti-HER2 containing therapy and/or chemotherapy in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprises the determination of the expression level of at least one of the following 12 genes: CCLS, CD21, CD80, CDBA, CTLA4, CXCL13, CXCL9, FOXP3, ID01, IGKC, PD1, PDL1 in a tumor sample from said patient, wherein said expression levels indicate a) the likelihood of benefit from inclusion of Carboplatin in a chemotherapy regimen; b) the likelihood of response to chemotherapy; c) the likelihood that the tumor is infiltrated with leucocytes; d) the likelihood of benefit from anti-HER2 containing therapy; e) the likelihood of developing metastases after treatment.